Clinic Software← All companies
Braveheart Bio
Transforming Hypertrophic Cardiomyopathy Care
health AI/medtech/pharma startup focused on hypertrophic cardiomyopathy
StageSeries A
Raised$185M
Employees27
LocationSan Francisco, CA
Business modelB2B/B2B2C SaaS-esque biotech translational model (clinical development and potential partnerships/licensing)
About
Braveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science investors including Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences (a platform of Patient Square Capital), and Frazier Life Sciences. Braveheart is advancing BHB-1893 through late-stage clinical development with the goal of establishing a new standard of care.
Product
- Value proposition
- Developing selective, small-molecule cardiac myosin inhibitors to improve heart performance in patients with hypertrophic cardiomyopathy (HCM) and advance global late-stage clinical development for BHB-1893 (HRS/BHB-1893).
- Target customers
- Hospitals, cardiology clinics, pharmaceutical partners, contract research organizations
- Regulatory
- Investigational; phase 2 results announced for HRS/BHB-1893; ongoing global late-stage development
Founders
- Travis Murdoch — Founder, CEO, and President
Categories
Products
BHB-1893 (HRS/BHB-1893)HCM investigational therapy
Key features
Selective cardiac myosin inhibitorEngineered to improve heart performance in HCMGlobal late-stage clinical developmentPartners with Hengrui Pharma for development/approval
Technologies
Small-molecule inhibitorCardiac myosin inhibitionClinical trial development
Target conditions
Hypertrophic Cardiomyopathy (HCM)Non-obstructive HCMObstructive HCM
Care settings
Clinical trialsHospital/academic medical centersResearch organizations
Certifications
FDA regulatory pathway (investigational)
Notable customers
Hengrui Pharma (partner)
Partnerships
Hengrui Pharma collaboration for HRS/BHB-1893 development
Traction metrics
Phase 2 results announcedGlobal late-stage development ongoing
Competitors
(not listed)
Investors
Andreessen HorowitzForbionOrbiMedEnavate SciencesFrazier Life Sciences
News
- Braveheart Bio Launches with $185M Series A Aiming to Transform Care of Hypertrophic Cardiomyopathy · 2025-11-05T11:00:00.000Z
- Braveheart, with Biogen CEO on board, rallies $185M series A · 2025-11-05T12:51:00.000Z
- Braveheart secures $185M to advance challenger to Bristol Myers heart drug | BioPharma Dive · 2025-11-05T06:00:00.000Z
- Braveheart Bio Bags $185M for Drug That Could Rival a Bristol Myers Squibb Cardio Med - MedCity News · 2025-11-06T21:10:38.000Z
- Cardio biotech Braveheart gets $185M, names Biogen CEO as its chair · 2025-11-05T11:00:13.000Z
- Bravehart, a stealthy startup, looks to China to challenge Bristol Myers heart drug | BioPharma Dive · 2025-09-05T10:20:24.000Z
